** Shares of British drugmaker Hikma Pharmaceuticals HIK.L fall 2% to 1,726p
** Co now expects full-year operating profit of $740 mln to $760 mln, compared with previous forecast of $720 mln to $770 mln
** Hikma reiterates overall annual revenue growth target of 2% to 4%, says demand across the Middle East and North Africa has remained robust
** As of last close, HIK up ~14% YTD
Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk
